10-QPeriod: Q1 FY2004

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2004

Filed May 10, 2004For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported a solid first quarter for 2004, demonstrating robust revenue growth driven primarily by its Companion Animal Group (CAG), which represents the largest segment of the business. Total revenue increased by 22% year-over-year, with CAG revenue up 25%. This growth was fueled by strong performance in rapid assays, instrument consumables, and laboratory services. The company also saw improved gross profit margins, expanding by 300 basis points to 50% of revenue, indicating effective cost management and favorable product mix. Net income grew significantly, reflecting the strong top-line performance and operational efficiencies. The company continues to invest in R&D and strategic acquisitions, as evidenced by the acquisition of a veterinary reference laboratory in Ohio. While facing competitive markets and regulatory landscapes, IDEXX appears to be executing well on its growth strategies, positioning it for continued expansion.

Key Highlights

  • 1Total revenue for the first quarter of 2004 increased by 22% to $133.4 million compared to $109.2 million in the prior year's quarter.
  • 2The Companion Animal Group (CAG) segment, the largest contributor, saw revenue growth of 25% to $109.8 million.
  • 3Gross profit increased by 30% to $67.0 million, with gross profit margin expanding to 50% from 47% in the prior year, showcasing improved operational efficiency.
  • 4Net income saw a substantial increase of 48% to $17.8 million, or $0.49 per diluted share, up from $12.1 million, or $0.34 per diluted share, in the same period last year.
  • 5The company repurchased $22.4 million of its common stock during the quarter under its ongoing share repurchase program.
  • 6IDEXX completed an acquisition of a veterinary reference laboratory in Ohio in February 2004 for $6.8 million, integrating it into its Companion Animal Group.
  • 7Operating expenses increased by 23% to $41.7 million, but as a percentage of revenue, they remained stable at 31%, indicating effective cost control relative to revenue growth.

Frequently Asked Questions